Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

In a landscape where access is no longer an after-thought, but a strategic imperative, this summit tackles the full lifecycle ...

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and Ultomiris (ravulizumab) – which are dosed by intravenous infusion every two and ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...